About
At Provectus, we are obsessed with technologies that impact the future of the whole of humanity. Just imagine: AI for curing eye diseases, ML for making factories safe for workers, preventing pandemic spreading, etc. It’s not about the future, it’s about the products we’ve already developed with ProvectusTeam.
Updates & Highlights
TradingView · 8 days ago
Provectus Biopharmaceuticals, Inc. Revenue Breakdown – OTC:PVCT
Investing.com South Africa · 10 days ago
Form 13D/A PROVECTUS BIOPHARMACEUTICALS For: 22 July By Investing.com
Stock Titan · 10 days ago
Provectus Biopharmaceuticals (PVCT) CEO holds 52.4M shares, 11.61% stake
Recent Openings
View all 6 jobs arrow_forwardAll Jobs
Culture & Mission
Benefits & Perks
Health Insurance
Medical, dental & vision
Remote Work
Work from anywhere flexibility
Learning Budget
Professional development
Generous PTO
Paid time off
Competitive Salary
Market-rate compensation
Equity/Stock Options
Ownership in the company
Tech Stack
Core Values
Innovation
Pushing boundaries in AI/ML technology
Collaboration
Working together to achieve more
Excellence
Striving for the highest quality
Impact
Making a difference in the world
Office Locations
Team
Are you on the team at Provectus?
Claim this company page to verify ownership, edit details, and respond to applicants.
Claim this company arrow_forwardNews & Press
20 recentProvectus Biopharmaceuticals, Inc. Revenue Breakdown – OTC:PVCT
Provectus Biopharmaceuticals, Inc. Revenue Breakdown – OTC:PVCT
TradingView · 8 days ago
Form 13D/A PROVECTUS BIOPHARMACEUTICALS For: 22 July By Investing.com
Form 13D/A PROVECTUS BIOPHARMACEUTICALS For: 22 July By Investing.com
Investing.com South Africa · 10 days ago
Provectus Biopharmaceuticals (PVCT) CEO holds 52.4M shares, 11.61% stake
Provectus Biopharmaceuticals (PVCT) CEO holds 52.4M shares, 11.61% stake
Stock Titan · 10 days ago
Form 13D/A PROVECTUS BIOPHARMACEUTICALS For: 22 July By Investing.com
Form 13D/A PROVECTUS BIOPHARMACEUTICALS For: 22 July By Investing.com
Investing.com Nigeria · 11 days ago
Croatian fund Provectus invests in Haelan Healthcare Group
Croatian fund Provectus invests in Haelan Healthcare Group
Капитал · 13 days ago
Dentons advises Invenio Partners on the sale of a majority stake in Haelan healthcare to Provectus Capital Partners
Dentons advises Invenio Partners on the sale of a majority stake in Haelan healthcare to Provectus Capital Partners
Legal Desire Media and Insights · 17 days ago
Dentons advises Invenio Partners on the sale of a majority stake in Haelan healthcare to Provectus Capital Partners
Dentons advises Invenio Partners on the sale of a majority stake in Haelan healthcare to Provectus Capital Partners
Dentons · 18 days ago
Bulgaria: Provectus Capital Partners acquires majority stake in Bulgarian private healthcare group and joins Invenio Partners in supporting growth
Bulgaria: Provectus Capital Partners acquires majority stake in Bulgarian private healthcare group and joins Invenio Partners in supporting growth
Investors in Healthcare · 19 days ago
Provectus enters Bulgaria with healthcare investment
Provectus enters Bulgaria with healthcare investment
EU.COM · 20 days ago
Croatia's Provectus to buy majority stake in Bulgarian healthcare group from INVENIO
Croatia's Provectus to buy majority stake in Bulgarian healthcare group from INVENIO
SeeNews · 23 days ago
French melanoma study finds the same dose of Provectus RBS can boost and suppress immunity
French melanoma study finds the same dose of Provectus RBS can boost and suppress immunity
Stock Titan · 26 days ago
Provectus (NASDAQ: PVCT) CEO updates Form 4 to correct Series D-1 preferred holdings
Provectus (NASDAQ: PVCT) CEO updates Form 4 to correct Series D-1 preferred holdings
Stock Titan · about 1 month ago
Provectus converts directors' accrued fees into Series D-1 Preferred Stock
Provectus converts directors' accrued fees into Series D-1 Preferred Stock
TradingView · about 1 month ago
Provectus (PVCT) swaps $542,500 director fees for Series D-1 preferred
Provectus (PVCT) swaps $542,500 director fees for Series D-1 preferred
Stock Titan · about 1 month ago
Provectus Biopharmaceuticals and VisiRose Announce U.S.
Provectus Biopharmaceuticals and VisiRose Announce U.S.
GlobeNewswire · about 1 month ago
Provectus (PVCT) director awarded Series D-1 convertible preferred stock grant
Provectus (PVCT) director awarded Series D-1 convertible preferred stock grant
Stock Titan · about 1 month ago
Provectus director granted Series D-1 preferred shares | PVCT Insider Trading
Provectus director granted Series D-1 preferred shares | PVCT Insider Trading
Stock Titan · about 1 month ago
Provectus Biopharmaceuticals and VisiRose Announce U.S. Patent Award for Light-Independent Antibacterial Eye Drop Targeting Drug-Resistant Ocular Infections
Provectus Biopharmaceuticals and VisiRose Announce U.S. Patent Award for Light-Independent Antibacterial Eye Drop Targeting Drug-Resistant Ocular Infections
Yahoo Finance · about 1 month ago
Enterprise value to EBIT forward of Provectus Biopharmaceuticals, Inc. – OTC:PVCT
Enterprise value to EBIT forward of Provectus Biopharmaceuticals, Inc. – OTC:PVCT
TradingView · about 1 month ago
Provectus launches Veripure™, providing pharmac...
Provectus launches Veripure™, providing pharmac...
Pluang · about 1 month ago